CN117202903A - 用于增加干细胞功能的尿石素 - Google Patents

用于增加干细胞功能的尿石素 Download PDF

Info

Publication number
CN117202903A
CN117202903A CN202280028511.7A CN202280028511A CN117202903A CN 117202903 A CN117202903 A CN 117202903A CN 202280028511 A CN202280028511 A CN 202280028511A CN 117202903 A CN117202903 A CN 117202903A
Authority
CN
China
Prior art keywords
urolithin
cells
stem cell
hspcs
population
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280028511.7A
Other languages
English (en)
Chinese (zh)
Inventor
M·吉罗特拉
N·万尼尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Societe des Produits Nestle SA
Ludwig Cancer Research
Original Assignee
Societe des Produits Nestle SA
Ludwig Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe des Produits Nestle SA, Ludwig Cancer Research filed Critical Societe des Produits Nestle SA
Publication of CN117202903A publication Critical patent/CN117202903A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Primary Cells (AREA)
CN202280028511.7A 2021-05-05 2022-05-02 用于增加干细胞功能的尿石素 Pending CN117202903A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21172290.5 2021-05-05
EP21172290 2021-05-05
PCT/EP2022/061666 WO2022233767A1 (en) 2021-05-05 2022-05-02 Urolithin for increasing stem cell function

Publications (1)

Publication Number Publication Date
CN117202903A true CN117202903A (zh) 2023-12-08

Family

ID=75825544

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280028511.7A Pending CN117202903A (zh) 2021-05-05 2022-05-02 用于增加干细胞功能的尿石素

Country Status (8)

Country Link
US (1) US20240228966A1 (cg-RX-API-DMAC7.html)
EP (1) EP4333832A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024516187A (cg-RX-API-DMAC7.html)
CN (1) CN117202903A (cg-RX-API-DMAC7.html)
AU (1) AU2022270331A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023022224A2 (cg-RX-API-DMAC7.html)
CA (1) CA3213384A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022233767A1 (cg-RX-API-DMAC7.html)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190328703A1 (en) * 2018-04-30 2019-10-31 Amazentis Sa Biological enhancer
CN111093656A (zh) * 2017-09-15 2020-05-01 小利兰·斯坦福大学托管委员会 用于保护、扩增造血干细胞和提高造血干细胞效力的线粒体醛脱氢酶2调节剂
WO2020148445A1 (en) * 2019-01-18 2020-07-23 Société des Produits Nestlé S.A. Agents and methods for increasing stem cell function

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723315A (en) 1996-08-23 1998-03-03 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
CZ297278B6 (cs) 1996-08-07 2006-10-11 Darwin Discovery Limited Deriváty hydroxamové a karboxylové kyseliny a jejich pouzití
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
WO2019163176A1 (ja) * 2018-02-21 2019-08-29 株式会社ダイセル ウロリチン類を含有する破骨細胞分化抑制剤

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111093656A (zh) * 2017-09-15 2020-05-01 小利兰·斯坦福大学托管委员会 用于保护、扩增造血干细胞和提高造血干细胞效力的线粒体醛脱氢酶2调节剂
US20190328703A1 (en) * 2018-04-30 2019-10-31 Amazentis Sa Biological enhancer
CN112512517A (zh) * 2018-04-30 2021-03-16 阿马曾提斯公司 作为免疫增强剂的尿石素a
WO2020148445A1 (en) * 2019-01-18 2020-07-23 Société des Produits Nestlé S.A. Agents and methods for increasing stem cell function

Also Published As

Publication number Publication date
AU2022270331A9 (en) 2023-10-19
JP2024516187A (ja) 2024-04-12
US20240228966A1 (en) 2024-07-11
AU2022270331A1 (en) 2023-10-12
CA3213384A1 (en) 2022-11-10
WO2022233767A1 (en) 2022-11-10
EP4333832A1 (en) 2024-03-13
BR112023022224A2 (pt) 2024-02-06

Similar Documents

Publication Publication Date Title
Hoorweg et al. Functional differences between human NKp44− and NKp44+ RORC+ innate lymphoid cells
JP7677893B2 (ja) 幹細胞機能を向上させるための薬剤及び方法
Kurtzberg et al. Preclinical characterization of DUOC-01, a cell therapy product derived from banked umbilical cord blood for use as an adjuvant to umbilical cord blood transplantation for treatment of inherited metabolic diseases
CN107072975A (zh) 用于造血干细胞药物中的方法和化合物
AU2017414804B2 (en) Selection and use of umbilical cord cell fractions suitable for transplantation
AU2018270407B2 (en) Selection and use of umbilical cord cell fractions suitable for transplantation
US20240010981A1 (en) Compositions and methods for increasing stem cell function
US20230365933A1 (en) Compositions and methods for increasing stem cell function
HK40104930A (en) Urolithin for increasing stem cell function
US20240228966A1 (en) Urolithin for increasing stem cell function
CN119899800A (zh) 从iPSC诱导分化NK细胞的方法
HK40058827A (en) Agents and methods for increasing stem cell function
CN101160391A (zh) 获得人造血干细胞群体的方法
HK40096626A (en) Compositions and methods for increasing stem cell function
HK40095240A (en) Compositions and methods for increasing stem cell function
Kurtzberg et al. Reprint of: Preclinical characterization of DUOC-01, a cell therapy product derived from banked umbilical cord blood for use as an adjuvant to umbilical cord blood transplantation for treatment of inherited metabolic diseases
Filip et al. Homing of lin−/CD117+ hematopoietic stem cells
CA3063674C (en) Selection and use of umbilical cord cell fractions suitable for transplantation
Imanirad et al. HIF1α is a regulator of hematopoietic progenitor and stem cell development

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40104930

Country of ref document: HK